| Ημερομηνία | barcode | code | περιεχομενο | τιμή παραγωγός | χονδρική | λιανική |
|---|---|---|---|---|---|---|
| 05/2018 | 2801194402018 | 119440201 | TARONTAL CON.R.TAB 400MG/TAB BTx20(BLIST2x10) | 2.69 | 2.84 | 04.06 |
For the treatment of patients with intermittent lameness or immobility arising from chronic occlusive arterial disease of the limbs.
Pentoxifylline inhibits erythrocyte phosphodiesterase, resulting in an increase in erythrocyte cAMP activity. Subsequently, the erythrocyte membrane becomes more resistant to deformity. Along with erythrocyte activity, pentoxifylline also decreases blood viscosity by reducing plasma fibrinogen concentrations and increasing fibrinolytic activity. It is also a non selective adenosine receptor antagonist.
LD<sub>50</sub>=1385 mg/kg(orally in mice)
0.4-0.8 hours
Excretion is almost totally urinary; the main biotransformation product is Metabolite V. Essentially no parent drug is found in the urine.